Marksans Pharma Ltd
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]
- Market Cap ₹ 13,318 Cr.
- Current Price ₹ 294
- High / Low ₹ 359 / 126
- Stock P/E 86.8
- Book Value ₹ 28.5
- Dividend Yield 0.20 %
- ROCE 14.7 %
- ROE 11.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 17.4%
Cons
- Stock is trading at 10.3 times its book value
- Company has a low return on equity of 12.1% over last 3 years.
- Company has high debtors of 158 days.
- Promoter holding has decreased over last 3 years: -4.38%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Allcap BSE Healthcare Nifty Total Market Nifty Microcap 250 BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
192 | 315 | 406 | 358 | 216 | 295 | 424 | 433 | 600 | 658 | 655 | 853 | 1,030 | |
148 | 231 | 290 | 254 | 191 | 266 | 361 | 362 | 486 | 545 | 563 | 713 | 860 | |
Operating Profit | 44 | 84 | 116 | 104 | 24 | 29 | 63 | 71 | 114 | 114 | 92 | 140 | 169 |
OPM % | 23% | 27% | 29% | 29% | 11% | 10% | 15% | 16% | 19% | 17% | 14% | 16% | 16% |
4 | 3 | 3 | 9 | 7 | 7 | 8 | 0 | 31 | 42 | 60 | 62 | 53 | |
Interest | 10 | 15 | 13 | 6 | 4 | 8 | 7 | 7 | 5 | 4 | 4 | 1 | 1 |
Depreciation | 9 | 9 | 9 | 15 | 15 | 12 | 9 | 12 | 15 | 18 | 17 | 29 | 30 |
Profit before tax | 30 | 63 | 97 | 92 | 12 | 17 | 56 | 53 | 124 | 135 | 132 | 172 | 192 |
Tax % | -34% | 12% | 31% | 22% | 3% | 25% | 22% | 28% | 21% | 23% | 22% | 22% | |
40 | 56 | 67 | 71 | 12 | 12 | 44 | 38 | 98 | 104 | 103 | 134 | 154 | |
EPS in Rs | 1.03 | 1.44 | 1.64 | 1.75 | 0.28 | 0.30 | 1.07 | 0.93 | 2.40 | 2.54 | 2.27 | 2.95 | 3.39 |
Dividend Payout % | 0% | 7% | 7% | 7% | 18% | 16% | 5% | 11% | 10% | 10% | 22% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 15% |
3 Years: | 12% |
TTM: | 45% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 25% |
3 Years: | 11% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 79% |
3 Years: | 73% |
1 Year: | 84% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 39 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 |
Reserves | 58 | 108 | 305 | 369 | 378 | 388 | 430 | 465 | 559 | 744 | 1,066 | 1,177 | 1,246 |
104 | 103 | 62 | 53 | 73 | 67 | 78 | 11 | 14 | 14 | 8 | 8 | 9 | |
110 | 127 | 119 | 71 | 54 | 61 | 64 | 83 | 127 | 167 | 226 | 285 | 337 | |
Total Liabilities | 310 | 376 | 527 | 534 | 546 | 557 | 612 | 600 | 741 | 966 | 1,345 | 1,516 | 1,637 |
73 | 67 | 90 | 97 | 94 | 88 | 103 | 115 | 129 | 136 | 144 | 272 | 308 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
Investments | 68 | 68 | 68 | 231 | 234 | 236 | 236 | 236 | 236 | 237 | 266 | 293 | 281 |
170 | 242 | 369 | 205 | 217 | 233 | 273 | 249 | 375 | 594 | 931 | 952 | 1,048 | |
Total Assets | 310 | 376 | 527 | 534 | 546 | 557 | 612 | 600 | 741 | 966 | 1,345 | 1,516 | 1,637 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 54 | 112 | 65 | -14 | 16 | 20 | 108 | 107 | 56 | 52 | 34 | |
-48 | -2 | -29 | -177 | -8 | -8 | -20 | -24 | 9 | -128 | -195 | -114 | |
22 | -19 | 51 | -52 | 21 | -10 | 1 | -82 | -14 | 71 | 210 | -26 | |
Net Cash Flow | -17 | 33 | 134 | -164 | -1 | -2 | 1 | 2 | 102 | -1 | 67 | -106 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 174 | 130 | 112 | 136 | 262 | 209 | 153 | 136 | 103 | 137 | 170 | 158 |
Inventory Days | 182 | 120 | 85 | 90 | 95 | 91 | 109 | 111 | 101 | 100 | 121 | 145 |
Days Payable | 106 | 87 | 75 | 64 | 67 | 73 | 58 | 84 | 69 | 72 | 103 | 122 |
Cash Conversion Cycle | 250 | 163 | 123 | 161 | 290 | 228 | 204 | 163 | 135 | 165 | 188 | 182 |
Working Capital Days | 101 | 82 | 69 | 133 | 300 | 232 | 193 | 147 | 94 | 116 | 144 | 144 |
ROCE % | 71% | 35% | 33% | 22% | 3% | 5% | 12% | 11% | 23% | 20% | 14% | 15% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Dec
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
25 Nov - Marksans Pharma Q2 FY25 earnings and strategy update.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
22 Nov - Marksans Pharma receives USFDA approval for Loratadine Tablets.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Audio recording of Q2&H1FY25 financial results call uploaded.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
Revenue Mix
Revenue Mix by therapeutic wise FY23[1]
Pain Management : 44%
Cough & Cold : 14%
Cardiovascular System : 9%
CNS: 8%
Anti-diabetic : 2%
Gastrointestinal : 9%
Others : 14%